Research programme: infectious disease vaccines - AltraVax
Alternative Names: Maxy-201Latest Information Update: 04 Nov 2017
At a glance
- Originator Maxygen; The Scripps Research Institute
- Developer AltraVax
- Class AIDS vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue; Hepatitis B; HIV-1 infections; Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in USA (Parenteral)